Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood test tell which lung cancer patients can skip chemo?

NCT ID NCT05457049

Knowledge-focused Sponsor: Guangdong Association of Clinical Trials Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are studying whether a blood test that looks for tiny traces of cancer DNA can identify early-stage lung cancer patients who are unlikely to need extra treatment after surgery. The trial enrolls adults with stage IB to IIIA non-small cell lung cancer who have had complete tumor removal and whose blood tests show no detectable cancer DNA. Participants receive regular blood tests every three months for two years to track whether the cancer returns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a blood test that detects tiny amounts of leftover cancer DNA, called molecular residual disease testing
What this could lead to
If the approach works, doctors could use a blood test to spare some early-stage lung cancer patients the side effects of chemotherapy they may not need.
What could go wrong
The study is observational and single-arm, so it cannot prove that skipping treatment is safe. Undetectable MRD may miss hidden cancer, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Stage IB-IIIA NSCLC patients who after complete resection and undetectable landmark MRD.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Stage IB-IIIA non-small cell cancer patients who after complete resection. * ≥18 years. * Two-round MRD tests confirm landmark undetectable MRD. * Expected survival ≥12 weeks. * Expected survival ≥12 weeks. * ECOG PS 1-2. * Willing to accept MRD monitoring every 3 months for a total of 2 years after operation. Exclusion Criteria: * Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy. * Patients with a history of other malignancies in the past 5 years. * Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences

    RECRUITING

    Guangzhou, Guangdong, 510080, China

  • Shantou Centeral Hospital

    RECRUITING

    Shantou, Guangdong, 515031, China

  • The First People's Hospital of Foshan

    RECRUITING

    Foshan, Guangdong, 528000, China

  • Zhongshan City People's Hospital

    RECRUITING

    Zhongshan, Guangdong, 528445, China

  • the First Affiliated Hospital of Shantou University Medical College

    RECRUITING

    Shantou, Guangdong, 515041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.